Literature DB >> 30778707

Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy.

Julia R Dahlqvist1, Grete Andersen2, Tahmina Khawajazada2, Christoffer Vissing2, Carsten Thomsen3, John Vissing2.   

Abstract

OBJECTIVE: Unlike most muscular dystrophies that progress symmetrically at a constant rate, facioscapulohumeral muscular dystrophy (FSHD) is characterized by stepwise, asymmetric progression of muscle wasting, and weakness. Muscle tissue is progressively replaced by fat; however, its relation to preceding inflammation is unclear. In this longitudinal study of FSHD, we assessed muscle inflammation and fat replacement and their relation quantitatively. We also investigated whether fat replacement in muscle varies along its length.
METHODS: Forty-five patients with FSHD were evaluated twice, 14 months apart. Using MRI sequences with short TI inversion recovery (STIR), we quantified the degree of STIR hyperintensity in muscles (≥ 2 SD above control intensity). STIR hyperintensities (STIR+) suggest edema or inflammation. We used Dixon MRI to quantify fat content.
RESULTS: Of 370 thigh muscles, 83 were STIR+ at baseline and 103 at follow-up. The highest frequency of STIR+ was seen in muscles with inter-mediate fat content (40-60% fat). The progression of fat replacement was higher in STIR+ muscles (5.0 ± 4.0%) vs. STIR- muscles [2.3 ± 3.3% (P < 0.0001)]. In addition, muscles with severe STIR+ at baseline had a higher fat replacement progression than muscles with milder STIR+ (R = 0.39, P = 0.001). The fat content was higher in the distal part vs. proximal part of most muscles (P < 0.05). However, the progression of the fat replacement was uniform along the length of all the muscles.
CONCLUSION: Muscles with STIR+, indicating inflammation, have a faster progression of fat replacement than STIR- muscles, and the fat replacement progression correlated with the severity of STIR+.

Entities:  

Keywords:  Dixon; FSHD; Facioscapulohumeral muscular dystrophy; MRI; STIR

Mesh:

Substances:

Year:  2019        PMID: 30778707     DOI: 10.1007/s00415-019-09242-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

1.  Elevated plasma complement components in facioscapulohumeral dystrophy.

Authors:  Chao-Jen Wong; Leo Wang; V Michael Holers; Ashley Frazer-Abel; Silvère M van der Maarel; Rabi Tawil; Jeffrey M Statland; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2022-06-04       Impact factor: 5.121

2.  Random forest: random results or meaningful insights for patients with facioscapulohumeral muscular dystrophy?

Authors:  Lindsay N Alfano; Tahseen Mozaffar
Journal:  Brain       Date:  2021-12-16       Impact factor: 15.255

Review 3.  Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy.

Authors:  Justin Cohen; Alec DeSimone; Monkol Lek; Angela Lek
Journal:  Trends Mol Med       Date:  2020-10-19       Impact factor: 11.951

4.  Adapting MRI as a clinical outcome measure for a facioscapulohumeral muscular dystrophy trial of prednisone and tacrolimus: case report.

Authors:  Leo H Wang; Laura M Johnstone; Michael Bindschadler; Stephen J Tapscott; Seth D Friedman
Journal:  BMC Musculoskelet Disord       Date:  2021-01-09       Impact factor: 2.362

5.  Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers.

Authors:  Anita van den Heuvel; Saskia Lassche; Karlien Mul; Anna Greco; David San León Granado; Arend Heerschap; Benno Küsters; Stephen J Tapscott; Nicol C Voermans; Baziel G M van Engelen; Silvère M van der Maarel
Journal:  Sci Rep       Date:  2022-01-26       Impact factor: 4.379

6.  Identification of Serum Interleukin 6 Levels as a Disease Severity Biomarker in Facioscapulohumeral Muscular Dystrophy.

Authors:  Marilyn Gros; Andreia M Nunes; Douglas Daoudlarian; Jonathan Pini; Emanuela Martinuzzi; Susana Barbosa; Monique Ramirez; Angela Puma; Luisa Villa; Michele Cavalli; Nicolae Grecu; Jérémy Garcia; Gabriele Siciliano; Guilhem Solé; Raul Juntas-Morales; Peter L Jones; Takako Jones; Nicolas Glaichenhaus; Sabrina Sacconi
Journal:  J Neuromuscul Dis       Date:  2022

7.  Dynamic magnetic resonance imaging of muscle contraction in facioscapulohumeral muscular dystrophy.

Authors:  Xeni Deligianni; Francesco Santini; Matteo Paoletti; Francesca Solazzo; Niels Bergsland; Giovanni Savini; Arianna Faggioli; Giancarlo Germani; Mauro Monforte; Enzo Ricci; Giorgio Tasca; Anna Pichiecchio
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

8.  Reduced specific force in patients with mild and severe facioscapulohumeral muscular dystrophy.

Authors:  Saskia Lassche; Nicol C Voermans; Tim Schreuder; Arend Heerschap; Benno Küsters; Coen Ac Ottenheijm; Maria Te Hopman; Baziel Gm van Engelen
Journal:  Muscle Nerve       Date:  2020-10-15       Impact factor: 3.217

9.  Quantitative 1H and 23Na muscle MRI in Facioscapulohumeral muscular dystrophy patients.

Authors:  Teresa Gerhalter; Benjamin Marty; Lena V Gast; Katharina Porzelt; Rafael Heiss; Michael Uder; Stefan Schwab; Pierre G Carlier; Armin M Nagel; Matthias Türk
Journal:  J Neurol       Date:  2020-10-12       Impact factor: 4.849

10.  Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy.

Authors:  Leo H Wang; Dennis W W Shaw; Anna Faino; Christopher B Budech; Leann M Lewis; Jeffrey Statland; Katy Eichinger; Stephen J Tapscott; Rabi N Tawil; Seth D Friedman
Journal:  BMC Musculoskelet Disord       Date:  2021-03-10       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.